Potential biomarkers for the prognosis of gastrointestinal stromal tumors  

作　　者：Yue-Fang Sun Xuan-Ke Cao Qing Wei Yao-Hui Gao 

机构地区：[1]Department of Pathology,Shanghai Tenth People’s Hospital,Tongji University School of Medicine,Shanghai 200000,China

出　　处：《World Journal of Gastrointestinal Oncology》2025年第4期31-35,共5页世界胃肠肿瘤学杂志(英文)

摘　　要：In this editorial we comment on the article published in the recent issue of World Journal of Gastrointestinal Oncology.This study aims to explore the relationship be-tween preoperative inflammation markers and the recurrence of gastrointestinal stromal tumors(GIST)after surgery.It is well known that the best-documented prognostic parameters for GIST are mitotic activity,tumor size and anatomical site.Besides,mutation status represents a prognostic as well as predictive factor.This study provides a new tool for postoperative recurrence risk assessment of GIST patients by establishing a line chart prediction model,which is certificated by previous research that high platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio correlated with increased tumour sizes,more advanced tumour stages and mitotic index.However,as a retrospective study,inevitable bias exists in the results;furthermore,the sample size of this study is relatively small,in-fluencing the universality of the results.Moreover,when assessing risk rating and prognosis of GIST,some novel inflammatory makers could be taken into consi-deration,such as proenkephalin and SLITRK3.Overall,this study can offer an additional model for GIST prognosis and recurrence risk assessment,indepen-dent of the traditional prognostic factors of GIST.

关 键 词：Gastrointestinal stromal tumors Prognostic parameters Inflammatory markers Recurrence risk Personalized therapy 

分 类 号：R73[医药卫生—肿瘤]